PPI Dosing Per CYP2C19 Genotype

Authors
Category Primary study
Registry of TrialsClinicalTrials.gov
Year 2026
This study is being done to determine if the dosing of proton pump inhibitor (PPI) medication based on CYP2C19 genotype-derived phenotype leads to improved healing of erosive esophagitis compared to conventional PPI medication dosing.
Epistemonikos ID: 0e4099abad3a4cc394bf4355dea40c9b6ce2e83e
First added on: Sep 29, 2026